Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

BACKGROUND: Integrase inhibitor (INSTI) with boosted darunavir (DRV/r), a regimen with a high-resistance barrier, avoiding NRTI toxicities, might be a switching option in children living with HIV (CLWHIV). METHODS: SMILE is a randomised non-inferiority trial evaluating safety and antiviral efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Compagnucci, Alexandra, Chan, Man K., Saïdi, Yacine, Cressey, Tim R., Bamford, Alasdair, Riault, Yoann, Coelho, Alexandra, Nolan, Aoife, Chalermpantmetagul, Suwalai, Morkunaite, Gabija, Amuge, Pauline, Musiime, Victor, Violari, Avy, Cotton, Mark, Kekitiinwa, Adeodata R., Kaudha, Elizabeth, Groenewald, Marisa, Liberty, Afaaf A., Kanjanavanit, Suparat, Volokha, Alla, Bologna, Rosa, Pavia Ruz, Noris, Prieto Tato, Luis, Paioni, Paolo, Marques, Laura, Reliquet, Véronique, Niehues, Tim, Welch, Steven B., Ford, Deborah, Giaquinto, Carlo, Gibb, Diana M., Babiker, Abdel, Ramos Amador, Jose Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251070/
https://www.ncbi.nlm.nih.gov/pubmed/37304494
http://dx.doi.org/10.1016/j.eclinm.2023.102025

Ejemplares similares

Ejemplares similares